Literature DB >> 30279854

Successful combined intravenous and subcutaneous immunoglobulin treatment for intractable protein-losing enteropathy in a patient long after Fontan-type operation.

Yoshiyuki Kagiyama1, Shintaro Kishimoto1, Hironaga Yoshimoto1, Yoshiyuki Kudo1, Kenji Gotoh1, Kenji Suda1.   

Abstract

A 20-year-old patient, who had double outlet right ventricle, mitral atresia, pulmonary atresia, and bilateral superior vena cava and underwent successful lateral tunnel total cavo-pulmonary connection at 6 years old, presented with frequent watery diarrhea, general malaise, and tetany. He was known to have intractable protein-losing enteropathy (PLE) from 7 years of age that was resistant to various treatments. To keep hemodynamics stable, he required intravenous albumin infusion every day. Fontan fenestration partially improved his condition and allowed to stop albumin infusion, however still he showed muddy stool and cachexia with low serum albumin <20 g/L and immunoglobulin <3 g/L. Because of serious risk of infection, we placed him on regular subcutaneous immunoglobulin supplementation with rescue intravenous immunoglobulin that improved his PLE within a month and allowed him to be discharged. This case illustrates that immunoglobulin supplementation can be one of the choices of treatment for intractable PLE. <Learning objective: Combined subcutaneous and intravenous immunoglobulin infusion therapy can be one of the choices of treatment for intractable protein-losing enteropathy that does not respond to multiple medications.>.

Entities:  

Keywords:  Fontan type operation; Immunoglobulin therapy; Protein-losing enteropathy; Subcutaneous immunoglobulin supplementation

Year:  2017        PMID: 30279854      PMCID: PMC6149556          DOI: 10.1016/j.jccase.2017.09.007

Source DB:  PubMed          Journal:  J Cardiol Cases        ISSN: 1878-5409


  8 in total

1.  Intravenous immunoglobulin (IVIG) preparations induce apoptosis in TNF-alpha-stimulated endothelial cells via a mitochondria-dependent pathway.

Authors:  K Nakatani; S Takeshita; H Tsujimoto; I Sekine
Journal:  Clin Exp Immunol       Date:  2002-03       Impact factor: 4.330

2.  Acquired combined immunodeficiency associated with protein losing enteropathy complicating Fontan operation.

Authors:  S Chakrabarti; B R Keeton; A P Salmon; J J Vettukattil
Journal:  Heart       Date:  2003-10       Impact factor: 5.994

3.  Protein-losing enteropathy after the total cavopulmonary connection: impact of intravenous immunoglobulin.

Authors:  Louise B Zaupper; Bent W Nielsen; Troels Herlin
Journal:  Congenit Heart Dis       Date:  2011-10-20       Impact factor: 2.007

Review 4.  Protein-losing enteropathy after Fontan operation.

Authors:  Jack Rychik
Journal:  Congenit Heart Dis       Date:  2007 Sep-Oct       Impact factor: 2.007

Review 5.  Protein-losing enteropathy: case illustrations and clinical review.

Authors:  Sarah B Umar; John K DiBaise
Journal:  Am J Gastroenterol       Date:  2009-09-29       Impact factor: 10.864

6.  Protein-losing enteropathy after fontan operation: investigations into possible pathophysiologic mechanisms.

Authors:  Adam M Ostrow; Hudson Freeze; Jack Rychik
Journal:  Ann Thorac Surg       Date:  2006-08       Impact factor: 4.330

7.  Intravenous immunoglobulin skews macrophages to an anti-inflammatory, IL-10-producing activation state.

Authors:  Lisa K Kozicky; Zheng Yu Zhao; Susan C Menzies; Mario Fidanza; Gregor S D Reid; Kevin Wilhelmsen; Judith Hellman; Naomi Hotte; Karen L Madsen; Laura M Sly
Journal:  J Leukoc Biol       Date:  2015-07-27       Impact factor: 4.962

8.  Protein-losing enteropathy in patients with Fontan circulation: is it triggered by infection?

Authors:  Dominik Lenz; Jörg Hambsch; Peter Schneider; Hans-Jürgen Häusler; Ursula Sauer; John Hess; Attila Tárnok
Journal:  Crit Care       Date:  2003-03-03       Impact factor: 9.097

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.